NCCN Awards Research Grants to Eight Investigators to Support Clinical and Pre-Clinical Studies of Mirvetuximab Soravtansine in Various Cancers
The NCCN Oncology Research Program has awarded research grants to eight investigators to study the effectiveness of mirvetuximab soravtansine in folate receptor alpha-positive cancers.FORT WASHINGTON, PA — The National Comprehensive Cancer Network ® (NCCN ®) Oncology Research Program (ORP ) has awarded eight grants to investigators to support clinical and pre-clinical studies of mirvetuximab soravtansine (IMGN853) and advance scientific knowledge of its uses in ovarian and other folate receptor